Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending August 2012. The report details a specific share repurchase transaction executed on August 23, 2012, pursuant to shareholder authority granted at the Annual General Meeting on May 3, 2012.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on capital structure and share repurchase activity.
- Shares Purchased: 1,400,000 Ordinary Shares of 25 pence each.
- Price Range: Highest price paid was 1,456.5 pence per share; lowest price paid was 1,442 pence per share.
- Treasury Holdings (Settled): 492,508,927 shares (9.00% of total issued share capital).
- Treasury Holdings (Including Unsettled): 496,058,927 shares (9.96% of current total voting rights).
- Shares in Issue (Excluding Treasury): 4,979,557,781 shares.
Material Changes
The primary material change is the reduction of outstanding shares through the purchase of 1,400,000 shares on August 23, 2012. This transaction increased the proportion of shares held in Treasury from the prior level to 9.00% of issued capital (9.96% of voting rights including unsettled shares).
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, management commentary on operations, or discussion of risks and contingencies. It is a compliance disclosure under the Financial Services Authority's Disclosure and Transparency Rules regarding share buybacks.
Investor Verification Checklist
- Verify the total cost of the 1,400,000 share repurchase based on the weighted average price between 1,442 and 1,456.5 pence.
- Confirm the impact of the 9.96% treasury holding on the denominator for shareholder notification thresholds under Disclosure and Transparency Rules.
- Check subsequent filings to determine if the unsettled shares (difference between settled and total treasury holdings) were fully settled.